Shortly after its spinoff and IPO, WuXi Biologics’ subsidiary WuXi XDC has locked up a major customer on its quest to establish itself as a premier bioconjugation co...

The FDA’s letter demanding a labeling change for Gilead Sciences’ Tecartus temporarily went missing on the agency’s website Tuesday. Turns out, the FDA didn’t drop t...

LogiPharma, the world's largest life sciences supply chain event has unveiled its highly anticipated 2024 agenda, spotlighting key themes and speakers for this year'...

Three years after bringing Jaguar Gene Therapy out of stealth, Deerfield Management is leading the funding of a manufacturing spinout from the Illinois company. D...

After years of patent litigation between cancer drug developers Daiichi Sankyo and Seagen, the U.S. Patent and Trademark Office (U.S. PTO) has handed Daiichi th...

GSK is sticking to its plan to gradually monetize its stake in Haleon, the consumer health business the British pharma giant spun off in 2022. GSK has collected a...

Taiwan-based CDMO Bora Pharmaceuticals is expanding its business in the United States, acquiring Minnesota generics manufacturer Upsher-Smith Laboratories for $210 m...

After many years of tracking the pharmaceutical industry’s pricing tactics, the Institute for Clinical and Economic Review (ICER) is once again placing a spotlight o...

Less than a week after gaining its first of what it hopes are several FDA approvals for its oral Factor B inhibitor Fabhalta (iptacopan) for blood disorders, Novarti...

Sanofi has been in the Egyptian manufacturing game for decades, but that doesn’t mean the French pharma can’t use a helping hand from time to time. Take for insta...